The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study

Andrew J. Cowan, Helen Baldomero, Yoshiko Atsuta, Joseph Mikhael, Mahmoud Aljurf, Adriana Seber, Hildegard Greinix, Mickey Koh, Nina Worel, Edward N. Libby, Marcelo Pasquini, Sebastian Galeano, Wael Saber, Minako Iida, Gregorio Jaimovich, Juliana Martinez Rolon, Yoshihisa Kodera, Malek Benakli, Bazuaye G. Nosa, Alaa ElhaddadJeff Szer, Jakob Passweg, Nicolaus Kroeger, Daniel Weisdorf, Dietger Niederwieser

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Multiple myeloma (MM) is a plasma cell neoplasm characterized by destructive bony lesions, anemia, and renal impairment. Access to effective therapy is limited globally. We report the rates and utilization of hematopoietic cell transplantation (HCT) globally from 2006-2015 to better characterize access to HCT for patients with MM. This was an analysis of a retrospective survey of Worldwide Network of Blood and Marrow Transplant sites, conducted annually between 2006-2015. Incidence estimates were from the Global Burden of Disease study. Outcome measures included total number of autologous and allogeneic HCTs by world regions, and percentage of newly diagnosed MM patients who underwent HCT, calculated by the number of transplants per region in calendar year/gross annual incidence of MM per region. From 2006 to 2015, the number of autologous HCT performed worldwide for MM increased by 107%. Utilization of autologous HCT was highest in Northern America and European regions, increasing from 13% to 24% in Northern America, and an increase from 15% to 22% in Europe. In contrast, the utilization of autologous HCT was lower in the Africa/Mediterranean region, with utilization only changing from 1.8% in 2006 to 4% in 2015. The number of first allogeneic HCT performed globally for MM declined after a peak in 2012 by -3% since 2006. Autologous HCT utilization for MM has increased worldwide in high-income regions but remains poorly utilized in Africa and the East Mediterranean. More work is needed to improve access to HCT for MM patients, especially in low to middle income countries.

Original languageEnglish (US)
Pages (from-to)2372-2377
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume26
Issue number12
DOIs
StatePublished - Dec 2020

Bibliographical note

Funding Information:
Financial disclosure: Andrew J Cowan: Consulting from Janssen. Advisory Board from Cellectar, Sanofi-Aventis. Research Funding from Bristol Myers Squibb, Janssen, AbbVie, Nektar, Conflict of interest statement: There are no conflicts of interest to report. Financial disclosure: See Acknowledgments on page 2376.

Publisher Copyright:
© 2020 American Society for Transplantation and Cellular Therapy

Keywords

  • Multiple myeloma
  • disparities
  • global
  • hematopoietic cell transplantation

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't

Fingerprint

Dive into the research topics of 'The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study'. Together they form a unique fingerprint.

Cite this